DNAprint Genomics (DNAG)

[SlopsterSlasher]

Also by worktoplay - By: worktoplay
08 Jul 2004, 11:59 PM EDT
Msg. 304759 of 304845
(This msg. is a reply to 304755 by worktoplay.)
Jump to msg. #
Terry...One more thing...

http://www.prbpharmaceuticals.com/RD/

RESEARCH AND DEVELOPMENT

Our approach to research and development is rigorously scientific, unbiased and open-minded.

In the United States, PRB Pharmaceuticals maintains extensive collaborative relationships with scientists at the University of Southern California and University of South Florida, and in Asia with the Chinese University of Hong Kong.

Our general approach is to screen thousands of compounds for their therapeutic properties. Candidate compounds are then formulated into OTC products or further fractionated, screened, and purified to produce lead molecules for ethical pharmaceutical development. This results in a rapid transformation of platform technologies into viable treatments and therapies.

We are currently conducting anti-viral research at the University of Southern California. We are also conducting laboratory research and clinical trials related to influenza virus, SARS coronavirus, and other viral diseases at the Prince of Wales Hospital in Hong Kong.

Plans are underway to create a new anti-viral, high throughput screening laboratory and a state-of-the-art drug discovery laboratory.

We ensure that all our treatments and therapies are rigorously tested and safe before releasing them on the market, and we provide extensive data in the Patient Product Information (PPI) distributed with our products.

PRB Pharmaceuticals' open-minded and scientific approach leaves no stone unturned in the pursuit of better solutions.

This is from Arch's Research posted last night (Thanks GCBR):

Shaanxi Yangling Daiying Biological Engineering Ltd. The Group entered into a letter of intent dated 30 June 2001 with Shaanxi Yangling Daiying Biological Engineering Ltd.(“Shaanxi Daiying ”)under which the parties agreed to establish a screening system for screening drugs for Hepatitis C in collaboration using the SimBioDAS ™technology. Shaanxi Daiying, an independent third party, is engaged in research on biological engineering and is specialised on the research and development of methods for treatment of Hepatitis C virus. Further details of the collaboration are subject to further negotiation and mutual agreement.

And just so people understand what this SimBioDAS Technology does:

The main bottleneck in the development process before a drug candidate is introduced into humans is predicting the degree to which a drug candidate taken by mouth will be absorbed through the intestine and into the body. To help to solve this bottleneck, the Group has focused its research program on developing a platform technology called the SimBioDAS ™ technology to predict how well a drug candidate will be absorbed into the human body. This system will be used to screen drug candidates for their absorption properties as part of an automated screening program leading to decisions on which drug candidates to be brought forward for further development.

The need for PK/PD information is not restricted to western medicines. Natural products,including TCM and nutraceuticals,are comprised of complex mixtures of active ingredients,and ingredients with pharmacological activity must be absorbed to exert their activity in the body. In order to have an effective formulation based on natural products,the absorbable active ingredients should be identified in the raw herbs and then their activities and absorbability should be confirmed in the marketed product. This information is missing in regard to the majority of TCM products and nutraceuticals,so there is little basis for the quality control now demanded by consumers and regulatory agencies like the FDA.Identifying active ingredients has been a difficult task, but the Directors believe that with the proprietary technology being developed by the Group, the Group is poised to solve this major problem.

The emerging SimBioDAS ™technology is an in vitro screening system through which the Group aims to help shorten the drug development timeline,thereby reducing the cost and resources required for the pre-clinical drug development process.The amount of time that can be saved by using the SimBioDAS ™ technology in the drug development process cannot be generalized in any specific instance. It depends on various factors, including in which stage of the drug development process is the SimBioDAS ™technology being used and whether the SimBioDAS ™ technology is used in different stages in the process. The Directors believe that the SimBioDAS ™technology could shorten the drug development time by a few months to more than a year, depending on the situation. On the basis that it costs an average of US$500 million and 10 years to discover and develop a drug, every week is about US$1 million on average. Thus the saving of even a few weeks in the process could make using the SimBioDAS ™ technology cost effective.

The SimBioDAS ™ technology is intended to work in the following areas:

–to help pharmaceutical companies focus on developing drug candidates that are well-absorbed by humans;

–to predict pharmacokinetics,especially absorption,of drug candidates in animals using an in vitro system; and

–to predict possible pharmacokinetic and toxicity problems with drug candidates in humans by revealing the potential differences between animal and human absorption of screened compounds.

In summary,the SimBioDAS ™technology aims to contribute to the lead identification process and facilitate rapid decisions on compound selection for further development and on discontinuation of less well-absorbed candidates. The SimBioDAS ™technology is expected to be adapted to predict the absorption of ingredients in TCM in humans. The Group also intends to develop a related biotechnological method to effectively isolate the active ingredients in natural herbal products. Using the Group ’s expertise and technology,the Group aims to test and develop novel high quality TCM formulations as drug products for the world market.

Later,
W2P